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Abstracts / Biol Blood Marrow Transplant 19 (2013) S194eS210S206adequate B cell function and are still dependent on IVIG
infusions. All 5 patients with absence of B cell function had
less than 25% B cell donor engraftment and 3 of them had
received ablative conditioning. Less than 25% donor B cell
engraftment correlated with abscense of function (P ¼
.006). 4/5 patients with absent B cell function have IL2RG
genetic defect (OR¼5.12, P ¼ .038). All the recipients of
MMUCB achieved faster and more reliable B cell function
compared to other donor sources (P ¼ .003). Hence absence
of adequate B cell function is most closely associated with
pts who have IL2RG defect irrespective of conditioning. In
addition, donor source inﬂuence the speed and probably
the ultimate success of B cell engraftment (MMUCB>haplo
donors).186
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TKIs are known to affect T and NK cells. We therefore
assessed immunological reconstitution and function in 24
pts with advanced CML and Ph+ ALL who received Nicotinib
as maintenance therapy post alloSCT (study CAM-
N107AIL03T). At 6 months after alloSCT, 11 of 15 pts with
advanced CML had attained CCyR, 11 of 15 pts with advanced
CML had attained a MMR or better, and 5 of 7 pts with Ph+
ALL attained a CR. The median OS was 16 months, with
predicted 1- and 2- year rates of 55% (95% CI, 32% e 72%) and
50% (95% CI, 28%e 68%), respectively. The median PFS was 11
months, with predicted 1- and 2- year rates of 50% (95% CI,
28% e 68%) and 38% (95% CI, 17% e 59%), respectively.
Immunological testing was performed pre- and post Niloti-
nib maintenance therapy in 12 pts in this study. The relative
percentage of T- lymphocyte subsets (assessed by FACS) and
total lymphocytes number were stable during Nilotinib
maintenance therapy, while a 7.82.5 fold increase in B cells
was noted. T cell mitogenic response with aCD3 and PHA
(stimulation index ratio) was sustained (2.51.0, vs. 2.81.05
and 3.31.3 vs. 5.32.9 stimulation. Mean thymic output
determined by TREC quantiﬁcation pre-, during and post
Nilotinib administration was 81.8108, 81.290.3 andTable
3 Months after dUCBT
dmPGE2-
dominant
Untreated/
Untreated-
dominant
P value -
T test
WBC 5900.0 4850.0 0.377
CD3+ count 10.6 50.0 0.097
% CD3+ of lymphocytes 2.55% 11.00% 0.066
Richness Alpha Diversity 585 3905
Clonality 1-Normalized
Entropy
0.1381 0.2454 0.090
Total Repertoire Overlap Index
Persistence of Top 10 Clones142.8197.4 copies per 0.5ug DNA indicating continuous
thymopoiesis. Similarly, no signiﬁcant change of the TCR
repertoire was observed during Nilotinib treatment. Normal
expression of the TCR repertoire was detected in 15.15.5
and 15.35.6 of the examined TCRs. NK cytotoxic activity
against K562 expressed as fold of change from baseline, also
remained stable during Nilotinib treatment (2.81.1 and
2.30.8, respectively). In summary, Nilotinib maintenance
therapy post alloSCT in pts with advanced CML and Ph+ALL
did not interfere or jeopardized immune reconstitution and
function.187
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In double umbilical cord blood (UCB) transplantation
(dUCBT), ex vivo modulation of a single UCB unit with 16,
16 dimethyl prostaglandin E2 (dmPGE2) accelerates
neutrophil engraftment and leads to preferential hemato-
poietic dominance with complete T cell chimerism as early
as 13 days from dUCBT. We sought to determine whether
dmPGE2 affected the recovery of T cell diversity after
dUCBT.
Methods: dUCBT recipients received ﬂudarabine, melphalan,
and ATG conditioning with Tacrolimus and Sirolimus GvHD
prophylaxis. TCRb CDR3 regions were ampliﬁed and
sequenced using the ImmunoSeq assay (Adaptive Biotech-
nologies) from a median of 171 ng of T cell gDNA (range 0.8 -
400.0 ng) at 3 and 12 months from dUCBT. We analyzed 5
paired samples with dmPGE2-dominance (PD); 3 paired and
7 single 12 month untreated (U) samples; and 5 paired and 1
single 12 month dmPGE2 treated sample with untreated-
dominance (UD). The U+UD groups were combined as one
control cohort.
Results: PD CD3+ cells were lower at 3 months versus the
U+UD group (P ¼ .057, Table) but this trend diminished by 12
months (P ¼ .11). Lower CD3+ counts were reﬂected in lower
total TCR alpha diversity in PD samples at both time points (3
month median 585 vs. 3905 unique TCR sequences, P ¼ .079;12 Months after dUCBT
P value -
U test
dmPGE2-
dominant
Untreated/
Untreated-
dominant
P value -
T test
P value -
U test
1 4300.0 6500.0 0.049 0.035
0.26 159.4 444.2 0.016 0.014
0.057 12.30% 31.85% 0.161 0.11
0.079 2729 12062.5 0.22
0.19 0.1105 0.2326 0.945 0.54
0.0873 0.3884 0.027 0.057
2 10 0.040
